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Abstract
Background: Semaphorins were originally identified as molecules regulating a functional activity of axons in the
nervous system. Sema4A and Sema4D were the first semaphorins found to be expressed on immune cells and
were termed “immune semaphorins”. It is known that Sema4A and Sema4D bind Tim-2 and CD72 expressed on
leukocytes and PlexinD1 and B1 present on non-immune cells. These neuroimmune semaphorins and their
receptors have been shown to play critical roles in many physiological and pathological processes including
neuronal development, immune response regulation, cancer, autoimmune, cardiovascular, renal, and infectious
diseases. However, the expression and regulation of Sema4A, Sema4D, and their receptors in normal and allergic
lungs is undefined.
Results: Allergen treatment and lung-specific vascular endothelial growth factor (VEGF) expression induced
asthma-like pathologies in the murine lungs. These experimental models of allergic airway inflammation were used
for the expression analysis of immune semaphorins and their receptors employing immunohistochemistry and flow
cytometry techniques. We found that besides accessory-like cells, Sema4A was also detected on bronchial epithelial
and smooth muscle cells, whereas Sema4D expression was high on immune cells such as T and B lymphocytes.
Surprisingly, under inflammation various cell types including macrophages, lymphocytes, and granulocytes in the
lung expressed Tim-2, a previously defined marker for Th2 cells. CD72 was found on lung immune, inflammatory,
and epithelial cells. Bronchial epithelial cells were positive for both plexins, whereas some endothelial cells
selectively expressed Plexin D1. Plexin B1 expression was also detected on lung DC. Both allergen and VEGF
upregulated the expression of neuroimmune semaphorins and their receptors in the lung tissue. However, the
lung tissue Sema4A-Tim2 expression was rather weak, whereas Sema4D-CD72 ligand-receptor pair was vastly
upregulated by allergen. Soluble Sema4D protein was present in the lung lysates and a whole Sema4A protein
plus its dimer were readily detected in the bronchoalveolar (BAL) fluids under inflammation.
Conclusions: This study clearly shows that neuroimmune semaphorins Sema4A and Sema4D and their receptors
might serve as potential markers for the allergic airway inflammatory diseases. Our current findings pave the way
for further investigations of the role of immune semaphorins in inflammation and their use as potential therapeutic
targets for the inflammatory lung conditions.
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Semaphorins compose a large family of secreted and
membrane-bound glycoproteins that are divided into
eight subclasses, 1 to 7 and viral [1,2]. They were first
identified in the nervous system with a defined function
as axon guidance molecules. All semaphorins contain a
homologues sequence of approximately 500 aa in the
N-terminal extracellular domain [1,2]. The most charac-
terized receptors for semaphorins are plexins and neuro-
pilins [1,2]. Unrelated to plexins and neuropilins, Tim-2
and CD72 receptors expressed on immune cells interact
functionally with the members of class 4 family sema-
phorins [1,2]. Recent findings have demonstrated a new
role for semaphorins and their receptors in Th1/Th2
differentiation and inflammation [2-4].
As it was reported previously, in the immune system
Sema4A is preferentially expressed on DC and B cells
[1,2,5-7]. Sema4A has three known receptors, Tim-2,
Plexin B1, and Plexin D1 [5,6]. Plexin D1 was shown to be
expressed on endothelial cells [7], whereas Tim-2 (T cell,
Ig domain, mucin domain-2) expression was highly
restricted to activated T cells, preferentially to Th2 cells
[5,6]. A recent study by Yukawa K and associates [8] has
demonstrated that Sema4A can also bind and activate
Plexin B1. Sema4D (CD100) was found to be constitutively
expressed on T cells and its expression was upregulated
with T cell activation [1,2,9-11]. Low levels of Sema4D
were detected in naïve DC and B cells [2,12]. Sema4D uti-
lizes two known receptors, Plexin B1 and CD72 [9,11].
Plexin B1 mRNA transcripts were found in multiple tis-
sues [11,13]. The main cellular sources of Plexin B1 are
epithelial and endothelial cells [1,6,7]. A recently published
study showed that epithelial cells in the lung co-express
Sema4D and Plexin B1 as determined by immunohisto-
chemistry [13]. Moreover, it was proposed that Sema4D
uses Plexin B1 as a receptor only in nonlymphoid tissues
[14]. CD72, a 45 kDa type II transmembrane protein
belonging to C-type lectin family, has been described as a
major lymphocyte receptor for Sema4D [1,2,9-13]. CD72
expression was found to be restricted to B cells, DC and
macrophages [1,2,9-12].
Both neuroimmune semaphorins, Sema4A and Sema4D,
have complex and critical roles in the immune response
that can not be compensated by other family members
[1,2,6-13]. Previous studies have demonstrated that
Sema4A and Sema4D mRNA transcripts are expressed in
many tissues including the lung [5,9-14]. However, the cell
types expressing Sema4A and Sema4D ligands in the lung
tissue were not clearly defined. To define it, we performed
the analysis of lung tissue and cell subset’s immune sema-
phorin and their receptor expression in steady state and
allergic inflammatory conditions. For the latter, we used
transgenic (tg) mice over-expressing VEGF molecule in a
lung-specific manner [15] or WT mice treated with aller-
gen [16]. We show that allergen-treated WT mice display
the lung tissue pathology reminiscent to that observed in
human asthma with the dominating Th2-driven eosino-
philic lung infiltration. We also show here and in our pre-
vious report [15] that lung VEGF overexpression induces
asthma-like tissue alterations including inflammation,
parenchymal and vascular remodeling, edema, mucus
metaplasia, and myocyte hyperplasia.
We found the prevalent expression of Sema4D and
especially CD72 in the mouse lung which was not
restricted to immune cells only but was also found on
different subsets of lung resident and inflammatory cells.
In addition and importantly, we report here a compli-
mentary cell distribution of these molecules (T cells, B
cells, MHCII+ cells co-express a ligand and a receptor)
what might be important for the corresponding cell auto-
crine regulation. The expression of Sema4A and Tim-2
was weak in the lung but was prominent in the lymphoid
tissue. However, under acute allergic inflammation
Sema4A protein and its dimer were readily detected in
the BAL fluids. We found both plexins being expressed
on epithelial cells with a prominent upregulation of the
epithelial cell Plexin B1 expression under inflammation.
Allergen-induced Sema4A expression was detected on
the lung underlining epithelium smooth muscle cells sug-
gesting its potential critical role in the smooth muscle
function. We also report here that lung DC express
Plexin B1 suggesting its role in their activation and/or
function. Based on the previously defined specific mole-
cule expression pattern [1-12] and our current results,
we conclude that the Sema4A-Tim-2 and Sema4D-CD72
interactions may efficiently occur in both, lung and local
lymphoid tissues. We also conclude that the interactions
of neuroimmune semaphorins with Plexins might have
the specific functional outcomes in the lung as these
pairs are co-expressed on several subsets of lung resident
and immune cells. As an example, lung epithelial cells
co-express Sema4A and both Plexins and lung dendritic
cells co-express Sema4D and Plexin B1. As immune
semaphorins have been shown to critically non-redun-
dantly regulate the immune response to antigen in vitro
and in vivo, a detailed analysis of their specific tissue
expression is an important step in understanding their
role in the cell-cell interaction and function and in the
target tissue/organ disease regulation. Our data set the
ground for further investigations of immune semaphorin
modulation and function in lung diseases.
Methods
Mice
C57BL/6 mice were obtained from Jackson Laboratory.
VEGF tg mice [15] were provided by Jack A. Elias (Yale
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Page 2 of 14University). All experiments with the mice were
performed in compliance with the principles and proce-
dures outlined in the NIH Guide for Care and Use
of Animals and were approved by the University of
Maryland School of Medicine Animal Care and Use
Committee.
OVA-induced experimental asthma protocol
C57BL/6 mice (WT mice) were treated with OVA
(grade V, Sigma) as described previously [16] and
detailed in the Additional files section.
VEGF-induced lung inflammatory response
VEGF tg mice and WT animals were introduced to the
doxycyclin-containing water (0.5 g/L) for 7 days [15].
Bronchoalveolar lavage cell composition
BAL and lung tissues were obtained from euthanized
mice and processed as previously described [17,18].
Cytospin preparations were made with 200 μLo fB A L
fluid (Cytospin 2; Shandon Inc., Pittsburgh, PA) and
stained with Diff-Quick (Dade Behring, Deerfield, IL).
The differential cell counts were determined from 4
high-power fields.
RT-PCR
Conventional (myeloid) DC (cDC) were sorted from
lungs of WT and VEGF tg mice as described previously
[19]. Cells were then washed in medium at 1200 rpm for
5 min at 4°C. Total RNA (tRNA) was extracted from cell
pellet using TRIzol reagent (Invitrogen Life Technologies,
Carlsbad, CA) and chloroform isolation procedure com-
bined with the RNAeasy mini kit (Qiagen, Velencia, CA)
according to manufacturer’s instruction. One μg of tRNA
was transcribed into first strand cDNA using SuperScript
kit (Invitrogen Life Technologies, Carlsbad, CA). Then
500 ng of cDNA was used for PCR amplification. PCR
reaction products were run on 1.5% agarose gels and
visualized using ethidium bromide. Quantification of the
target gene expression was done by comparison with the
expression of b-actin. The gene specific primers for
RT-PCR were designed using the Primer3 Input 0.4.0
software. The amplicon specificity was verified by gel
running and/or by sequencing.
Histochemistry and immunohistochemistry
Frozen sections from WT and VEGF tg mouse lungs
were prepared as described in Additional files 1 and 2.
Paraffin-embedded tissues from PBS- or OVA-treated
mouse lungs (n = 3-4 mice per experimental group in
3-4 independent experiments) were prepared as
described in the Additional files. Unlabeled Abs against
intracellular portions of Sema4A (clone C-20) and
Sema4D (clone C-19), extracellular portions of Plexin
B1 (N-18) and D1 (E-13) were obtained from Santa
Cruz. Unlabeled anti-mouse CD72 (AF-1279) and Tim-2
(AF-1885) Abs were obtained from R&D Systems. Stain-
ings were visualized as detailed in the Additional files.
Staining specificity was assessed by evaluation of the
appropriate isotype control Ab stain. According to the
Ab’s datasheets, Abs were generated by immunization of
corresponding hosts with a corresponding purified
recombinant protein or a protein fragment. Each Ab
was then purified using the relevant Ag chromatogra-
phy. The specificity and quality of Abs used in our
assays was assessed by the manufacturer in Western
blot using lysates of Ag-transfected either EL-4 or 293T
cells and in direct ELISA.
Flow cytometry
Lung tissue collagenase (Worthington Biochemical Corp.,
L a k e w o o d ,N J )- D N A s e( R o c h e ,M a n n h e i m ,G e r m a n y )
digests were performed (n = 2-3 mice per experimental
group in 3-4 independent flow cytometry experiments)
and stained for FACS analysis as described previously
[19]. The following mAbs obtained from BD Biosciences
Pharmingen (San Diego, CA) were used: anti-I-Ab
b-PE
(AF6-120.1), anti-CD3-FITC or -PE (145-2C11), anti-
CD4-FITC or -PE (GK1.5), anti-CD8a-PerCP (53-6.7),
anti-CD11c-APC or -FITC (HL3), anti-B220/CD45R-
FITC (RA3-6B2), anti-GR1-PE (Ly-6G and Ly-6C), anti-
NK1.1-APC (PK136). Anti-Mac-1-PE-Cy-5 (CD11b/
CD18) Ab was obtained from Cedarlane Laboratories
and anti-Plexin B1 Ab (A-8) was purchased from Santa
Cruz. For the detection of CD72 and Tim-2, we
employed Abs used for IHC and, in addition, FITC-
labeled anti-CD72.1 (ab25029, Abcam) and biotinylated
anti-mouse Tim-2 Ab (RMT2-1, Biolegend). Biotin-
labeled anti-Sema4A (KL-1) and anti-Sema4D (BMA-12)
were obtained from eBioscience. FITC-labeled Sema4A
(5E3) and Sema4D (BMA-12) Abs were obtained from
Medical & Biological Laboratories, Japan. SAV-PerCP
and SAV-FITC were used as the second step reagents for
biotinylated Abs. FITC-conjugated or biotinylated rat
IgG1 (R3-34 or A110-1), mouse IgG1 (Sigma), rat IgG2a
(R35-95), rat IgG2b (R35-38) were used as isotype con-
trols. Plasmacytoid DC visualization was performed as
described in. Where necessary, cells were preincubated
with anti-CD16/CD32 (2.4G2) mAb for blocking cell sur-
face FcR. Cells were analyzed on FACSCalibur (Becton
Dickinson, San Jose, CA) flow cytometer using either
CELLQuest or FlowJo software.
Intracellular staining
Single cell suspensions from the lungs of PBS- or OVA-
treated mice were washed and placed in FACS buffer
with anti-CD16/CD32 Ab (BD Biosciences) to block
nonspecific binding (1 μg Ab/1 mln cells). Cell surface
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APC, anti-I-Ab
b-PE, and anti-Mac-1-PE-Cy-5 Ab speci-
fied above. Cell were washed, permeabilized, and stained
with FITC-anti-Sema4A (5E3) as described in the Addi-
tional files.
Western blot
Whole lung lysate preparation, protein extraction, basic
Western blot procedure, and protein detection were pre-
viously described [20]. Anti-Sema4D primary Ab (clone
Y-20) and HRP-conjugated donkey anti-goat secondary
Ab employed in this study were purchased from Santa
Cruz Biotechnology. 15 microliters of BAL fluids
obtained from either PBS- or OVA-challenged WT mice
were used for a detection of Sema4A expression using
anti-Sema4A primary Ab from MBL (clone 5E3) and
HRP-labeled donkey anti-mouse secondary Ab (sc-2414,
Santa Cruz). Both blots were performed in reducing
conditions using either the 4-20% Tris-HCl Gel from
BioRad (for Sema4D) or 10% Precise Protein Gel from
ThermoScientific (for Sema4A) with the Precision Plus
molecular weight marker (BioRad). ECL detection
reagents kit (Amersham Biosciences) was used according
to the manufacturer’s instruction.
Statistics
Data were summarized as mean ± SEM. To calculate
significance levels between experimental groups,
Student’s t test (Microsoft Excel) was performed.
Results
Monitoring of specific molecule expression was done in
C57BL/6 (WT) mice treated with either PBS or allergen
and in VEGF tg mice with 7 days of transgene induction
as described in Methods.
Allergen and VEGF induce asthma-like inflammatory
responses
Allergen treatment of WT mice induced a significant
influx of inflammatory cells into the lungs measured by
cell counts in the BAL and the H&E staining of lung tis-
sue (Figure 1 A and 1B). Eosinophils were found to
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Figure 1 Lung exposure to either allergen or VEGF induces asthma-like inflammatory responses. (A-B) WT mice were exposed to OVA as
described in the Methods section. Significant influx of eosinophils, lymphocytes, and neutrophils into BAL of allergen-treated WT mice was
found compared to PBS-treated counterparts (*p < 0.025, 0.045, and 0.03, correspondingly) (A). Lung tissue inflammatory response observed on
histology slides corresponds that in BAL (magnification x20, for insert 100x) (B). (C-D) Lung VEGF expression induces local inflammation and
upregulation of selected neuroimmune semaphorin and receptor molecules in sorted lung conventional DC. H&E staining of lungs from WT and
VEGF tg mice given DOX water for 7 days (magnification 40x) (C). Sorted mouse lung cDC were subjected to tRNA extraction followed by cDNA
preparation and PCR with gene-specific primers. Note a strong upregulation of Sema4D and CD72 in lung cDC by VEGF (D).
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ted mice mounting to 147,233 ± 61,999 cells whereas
they were absent in the BAL of PBS-treated mice (0 ±
0). Lung tissue histochemistry pictures corresponded
that of BAL cell composition (Figure 1 B).
We reported previously that VEGF tg mice developed
asthma-like phenotype with inflammation, parenchymal
and vascular remodeling, edema, mucus metaplasia,
myocyte hyperplasia and airway hyperresponsiveness
[15]. The tissue changes begin to occur in tg mice as
quickly as being 2 days on DOX-containing water and
progress significantly with time [15]. We show here a
significant lung pathology observed in tg mice on day 7
after tg expression initiation (Figure 1 C) with multiple
large inflammatory macrophages noted in the alveolar
spaces.
We also showed previously how lung VEGF expres-
sion functionally affects local conventional DC for the
transition from the innate response to a Th-2-type
inflammatory response [19]. VEGF regulates many
innate immunity molecules in cDC. To study if VEGF
has an effect on lung cDC expression of immune sema-
phorins and their receptors,w ea n a l y z e dm R N Al e v e l s
for selected specific semaphorins and receptors by RT-
PCR (Figure 1 D). cDC from VEGF tg mice exhibit
increased mRNA expression of Sema4A, Sema4D, and
CD72 as compared to analogous cells sorted from WT
mouse lungs. Upregulation of Sema4D was especially
prominent, whereas the expression of Plexin B1 was not
changed, and Sema4A was slightly induced in tg cDC.
Therefore, VEGF overexpression in the lung induces an
upregulation of specific neuroimmune semaphorins and
their receptors. Upregulation of neuroimmune sema-
phorin expression is a characteristic of activated DC
[1,2,5,10,12]. This observation let us to hypothesize that
VEGF- and allergen-induced lung tissue alterations are,
at least in part, immune semaphorin-dependent. Thus,
we focused our study on the expression of immune
semaphorins and their receptors in the lung tissue and
cells.
Regulation of lung Sema4A and Sema4D expression by
allergen and VEGF
Lung tissue immunohistochemistry with Ab for the intra-
cellular portion of Sema4A has shown that significant
numbers of cells with macrophage- and DC-like mor-
phology were positive for Sema4A in the control PBS-
treated mouse lungs (Figure 2 A). Sema4A expression in
the lung was increased during allergen-induced inflam-
mation due to the influx of the marker-positive cells (3.2
± 0.9 vs 6.2 ± 1.4 cells/high power 100x field, p < 0.042,
PBS- vs OVA-treated mice). Bronchial epithelial cells
showed a weak Sema4A expression whereas underlining
epithelium smooth muscle cells were strongly Sema4A-
positive (Figure 2 A). Isotype control Ab did not stain the
tested tissues (Additional files, Figure 1) indicating Ab
specificity and a definite upregulation of Sema4A in the
allergen-treated lungs. In contrast to its relatively low
expression in the lung tissue, Sema4A was readily
detected in the lymphoid tissue of allergen-treated WT
mice (Figure 2 B) and its expression was restricted, as
expected, to APC-like cells.
Using Ab for C-terminus of Sema4D for IHC, we
found an unusual pattern of Sema4D staining which was
not targeted to the cell cytoplasm but rather to cell bun-
dle-like shapes (Figure 2 A) in the lungs obtained from
both PBS- and OVA-treated mice. Its tissue expression
was not much modulated by allergen treatment as
assessed by IHC with this Ab (3.0 ± 0 vs 4 ± 0.6 cells/
high power 100x field, p < 0.08, PBS- vs OVA-treated
mice).
Similarly to C57BL/6 mice, in the VEGF tg mouse
lungs a substantial number of accessory-like cells was
stained positively for Sema4A (Figure 2 A). Tg expres-
sion upregulated the tissue expression of this sema-
phorin as there were more Sema4A+ cells in tg lungs.
Sema4D lung tissue expression was mainly detected in
APC-like cells and was significantly upregulated by
VEGF (Figure 2 A). This upregulation included both an
increase in the marker-positive cell numbers (3.2 ± 1.8
vs 8.4 ± 3.9 cells/high power 100x field, p < 0.04, WT
vs VEGF tg mice) and a brighter marker expression per
cell in tg lungs as defined by the intensity of staining.
It has been reported that under inflammation a mem-
brane-bound Sema4D gets cleaved by MT1-MMP and
sheds from the cell surface [19]. Indeed, employing Ab
to a soluble form of Sema4D (Y-20, Santa Cruz), we
found this molecule to be present in the lung tissue
lysates of OVA-treated but not PBS-treated WT mice
(Figure 2 C). Similarly, the soluble 120 kDa Sema4A
form was detected in the culture supernatants of
Sema4A-transfected cells (7). Therefore, it has been pro-
posed that Sema4A also sheds from the cell surface
under inflammatory conditions. When we used the BAL
fluids from either PBS- or OVA-challenged mice in
Western blot under conditions defined in the Methods
section, we found increased levels of the a whole 150
kDa Sema4A protein in the OVA-treated mice as com-
pared to PBS-treated counterparts (Figure 2 C). A weak
120 kDa band corresponding soluble Sema4A protein
was also detected under inflammation, however, a band
corresponding Sema4A dimer (>250 kDa) was much
more prominent.
Flow cytometry analysis of lung single cell suspensions
has shown that, in contrast to lymphoid organs, there
was no significant Sema4A expression on lung APC sur-
face (Figure 3 A). This included lung cDC which were
defined as CD11c+MHCII
low cells in PBS-treated mice
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Figure 2 Lung tissue Sema4A and Sema4D expression and their regulation by allergen and VEGF. (A) Formalin-fixed paraffin-embedded
lung tissue sections (top microphotographs) were deparaffinized and immunohistochemistry was performed employing Abs for the intracellular
portions of Sema4A and Sema4D molecules. Bottom photomicrographs show immunohistochemistry on frozen lung tissue sections obtained
from VEGF tg mice and control WT mice being on DOX water for 7 days. Sema4A expression in PBS-treated lungs was mainly limited to
macrophages and dendritic like-cells. Tissue Sema4A expression was upregulated with allergen treatment and VEGF exposure and detected on
APC-like cells and smooth muscle cells (both cell types marked with red arrows). Inserts show high magnification fields (100x) with marker-
positive cells. Sema4D expression was detected in cell bundle-like shapes (red arrows, inserts) in the lungs obtained from both PBS- and OVA-
treated mice. OVA treatment did not significantly modulate tissue levels of Sema4D. (B) Sema4A was abundantly expressed on APC-like cells
(inserts, red arrows) in lymphoid tissue of allergen-treated WT mice. (C) Soluble Sema4D protein (120kDa) was detected in lung tissue lysates
obtained from OVA-treated mice. Whole Sema4A protein (150 kDa), dimer (>250 kDa), and weak soluble Sema4A (120 kDa) were detected in
BAL fluids of OVA-challenged mice. Arrows point to the molecular weight protein standard reference bars.
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Page 7 of 14and as CD11c+/MHCII+ cells in OVA-treated mice
[19]. Low number of lung plasmacytoid (p)DC, which
were defined as CD11c
intermedB220+ cells [19], were
found to express Sema4A (from 7.5% to 17.9%, PBS vs
OVA-treated mice, data not shown). Intracellular stain-
ing of the lung cells obtained by an enzymatic tissue
digest has shown that Sema4A expression was predomi-
nantly targeted to a specific cell subset, namely CD11c
in-
termed MHCII
low cells (Figure 3 B) which could
potentially include pDC, precursors of conventional lung
DC, and a subset of lung macrophages [19,21,22]. Of
note, neither CD11c+MHCII- cells nor CD11c-MHCII+
cells evaluated showed measurable levels of intracellular
Sema4A (data not shown). Initial low level of lung cDC
Sema4D expression was further downregulated after
OVA treatment (Figure 3 A) possibly due to the pre-
viously described molecule shedding from the cell sur-
face in inflammation [11,23]. Indeed, the presence of an
extracellular portion of Sema4D (120 kB) in allergic but
not control lungs was confirmed by Western blot
employing tissue lysates (Figure 2 C).
As a control for the flow cytometry study of neuroim-
mune semaphorin expression on lung cells we used
spleen MNC where their expression was partially
defined previously [1,2,5,7-12]. We identified two spleen
DC subpopulations based on a dual marker for DC,
CD11c and MHCII, namely CD11c+MHCII- and CD11c
+MHCII+ (Figure 3 A). Interestingly, we have found
that in contrast to lung DC, both spleen CD11c+ popu-
lations express a substantial level of Sema4D and
Sema4A (Figure 3 A and data not shown). CD11c
+MHCII+ cells did not show any modulation of
immune semaphorin expression by allergen (data not
shown). CD11c+MHCII- cells, which might include DC
precursors, immature DC, and/or pDC [24,25] had sig-
nificantly higher constitutive levels of both molecules
when compared to CD11c+MHCII+ cells. Allergen
exposure increases the corresponding marker expression
on these DC (from 36.3% to 47.2% and from 64.9% to
71.9%, PBS vs OVA, Sema4A and 4D, respectively,
Figure 3 A).
As expected, lung T cells (CD3+ cells) did not express
much of Sema4A in both steady-state and inflammatory
conditions (Figure 3 C). In contrast, Sema4D molecule
was readily detected on T cells (Figure 3 C). Surpris-
ingly, lung B cells (B220+ cells) in PBS-treated mice
w e r ea l s of o u n dt ob eh i g h l yS e m a 4 D +( F i g u r e3C ) ,
although it has been reported previously that Sema4D is
weakly expressed on naïve B cells [2,12]. In PBS-treated
mice, around 45% of MHCII+ cells in the lung co-
expressed Sema4D whereas Sema4A expression on these
cells was negligent (Figure 3 D). The levels of cell
expression for both molecules did not change signifi-
cantly with OVA treatment. NK1.1+ cell number
increased in the inflamed lung (5.0% and 10.3% of total
cells, PBS- vs OVA-treated mice). These cells showed
low Sema4A (around 11%) but high Sema4D expression
(63.8%) which was downregulated by OVA (data not
shown).
Therefore, the overall presence of a membrane-bound
Sema4A molecule in the lung tissue is low. Thus, its
contribution to the lung inflammatory response regula-
tion is most probably restricted to the local lymphoid
tissue where it is abundantly expressed on CD11c+ cells.
In contrast, Sema4D is highly expressed on lung
immune cells (T and B cells), and, to a lower extend, on
lung MHCII+ cells which, in addition to the lung pro-
fessional APC, might include epithelial cells, fibroblasts,
mast cells, macrophages, and, under inflammation, gran-
ulocytes [26-29]. Thus, Sema4D can potentially regulate
lung inflammatory response both locally and in the lym-
phoid tissue.
Regulation of lung Tim-2 and CD72 expression by
allergen and VEGF
W en e x tp e r f o r m e dI H Ca n df l o wc y t o m e t r ys t u d i e st o
define the lung expression of Tim-2 and CD72, corre-
sponding Sema4A and Sema4D immune cell receptors.
As it has been shown previously, Tim-2 is a marker
for activated T cells, preferentially Th2 cells [5-7],
whereas CD72 is found to be expressed on B cells and
DC [9-12]. To our surprise, using Ab for IHC specified
in the Methods section, Tim-2 staining was detected on
many cells in the lungs of allergen-treated mice (Figure
4 A) including inflammatory macrophages and a subset
of granulocytes. This staining was specific when com-
pared to isotype control Ab staining (Additional files,
Figure 1). Some lymphocytes were also Tim-2-positive.
In VEGF tg mice Tim-2 was targeted predominantly to
the tissue lymphocytes with a weaker staining detected
in macrophages and granulocytes (Figure 4 A). In con-
trast to the lung tissue, strong Tim-2 expression was
readily detected in spleen and local lymph nodes of
allergen-treated WT mice (Figure 4 B). Flow cytometry
data had shown an increase in Tim-2-positive T cells in
allergic lung (mean of fluorescence intensity from 7.94
to 25.5%, PBS- vs OVA-treated mice, respectively) (Fig-
ure 4 C). The physiological mean of Tim-2 expression
on other cell types besides T cells has to be determined.
IHC demonstrated an abundant CD72 expression in
control murine lungs which was greatly pronounced
with inflammation (Figure 5 A). Lung accessory-like
cells (red arrow on the tissue picture obtained from a
PBS-treated mouse) and alveolar type II-like cells (mid-
dle photomicrograph) were CD72-positive. In addition,
we found CD72 to be expressed on bronchial epithelial
cells in large bronchi but rarely in smaller bronchi.
Alveolar macrophages were also CD72-positive. Under
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Page 8 of 14OVA-induced inflammatory conditions, some additional
cells such as subsets of lymphocytes, granulocytes, and
inflammatory macrophages were also found to express
CD72 (Figure 5 A). A pattern of CD72 expression in
WT control mice being on DOX water was similar to
that observed in PBS-treated WT mice although the
staining appears weaker (Figure 5 A). In VEGF tg mice
the expression of CD72 was noted mainly on lung
inflammatory macrophages and epithelial cells in large
bronchi (Figure 5 A). Flow cytometry assessment of
MHCII+ cells, DC and T cells showed the level of CD72
cell expression and its upregulation by allergen (Figure 5
B). As it has been reported previously, in the lymphoid
tissue CD72 is expressed on B cells, DC, and a small
fraction of activated T cells [1,2]. Indeed, in the murine
lungs MHCII+ cells express Sema4D receptor CD72
(Figure 5 B). In accord with our IHC data, CD72 was
also found to be expressed on lung DC and it was posi-
tively regulated by allergen. Interestingly, only a fraction
of lung T cells express CD72 which further increases for
CD4 + but not for CD8+ T cells after allergen treat-
ment. Therefore, CD72 can potentially be a useful mar-
ker for a specific cell subset’s activation status.
Regulation of lung Plexin D1 and B1 expression by
allergen and VEGF
Lastly, we performed IHC to define the lung tissue distri-
bution of Plexins D1 and B1, corresponding Sema4A and
Sema4D non-immune cell receptors. Previous studies
have shown both plexins to be expressed on endothelial
cells [26,27]. However, we showed here that mouse lung
endothelial cells did not stain positively for Plexin B1
(Figure 6 A). Around 20% of the lung bronchi and
bronchioles were found to express Plexin B1 while most
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Page 10 of 14of them were marker-negative. OVA treatment upregu-
lated this level to more than 50% of corresponding air-
ways (Figure 6 A). In addition, Plexin B1 expression was
noted on APC-like cells in the lung tissue. This was sup-
ported by the flow cytometry study which demonstrated
Plexin B1 expression on lung cDC (Figure 6 B).
In allergen-treated WT lungs, Plexin D1 expression
was mostly targeted to endothelial cells (Figure 6 A).
Some large bronchi demonstrated a weakly-positive
Plexin D1 staining in the apical portion of lining epithe-
lium if compared to Plexin B1 expression. In addition,
some APC-like cells in the bronchi basement membrane
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Page 11 of 14were found to be highly positive for this Sema4A recep-
tor under inflammatory conditions. VEGF-induced lung
inflammatory response clearly correlated with more
local Plexin expression as both Plexins were upregulated
in VEGF tg lungs (Figure 6 C). Whereas Plexins were
found predominantly on the epithelium of large bronchi,
notable inflammatory macrophage expression of both
molecules was found in tg mice.
Discussion
In this manuscript we demonstrated, for the first time, the
expression of neuroimmune semaphorins and their recep-
tors in the lung tissue and subsets of cells and compared it
to the previously published and obtained in our laboratory
results on the expression of these molecules in the
immune tissues. We show here that the lung tissue expres-
sion of neuroimmune semaphorins is more complex than
that shown previously for the immune and tumor cells
[5-14,30,31]. First, the expression of immune semaphorins
and their so-called “immune cell receptors” in the lung is
not restricted to immune cells but can be also found on
many resident and inflammatory cells. For example, the
most abundantly distributed in the lung CD72 molecule
was found to be present on the subsets of macrophages,
granulocytes, and lymphocytes as well as on alveolar
macrophages, alveolar type II-like epithelial cells, and
bronchial epithelial cells. These IHC results have to be
further confirmed using the specific cell surface markers
for the named above lung resident cell subsets. Second, we
showed a somewhat different distribution of neuroim-
mune semaphorins and their receptors in the lung tissue
as compared to the lymphoid organs. Specifically, we
defined that Plexin B1, a common receptor for both
Sema4A and Sema4D which was previously reported for
epithelial and endothelial cells [1,6,7], is also expressed on
lung DC (Figure 6 B). In addition, we detected Th2 cell
marker Tim-2 being expressed on several resident and
inflammatory cell subsets in the inflamed lung (Figure 4).
Finally, we identified the cells in the lung co-expressing a
specific ligand-receptor pair suggesting a possible critical
role of these molecules in the corresponding cell activation
and/or function.
Constitutively high Sema4A expression on the surface
of all mouse DC subsets, including BMDC, CD8+DC
and CD8-DC was reported previously [32]. We show
here that, in contrast to lymphoid organs, Sema4A was
practically absent on all lung MHCII+ cells (Figure 3 A
and 3D). Its expression was not detected on lung cDC,
was very low on lung pDC, T cells and B cells. As on
the IHC slides Sema4A expression was found to be
mainly targeted to APC-like cells with some cells show-
ing clear dendritic cell morphology (Figure 2 A plus
inserts), we performed a flow cytometry assay employing
Abs to the cell surface markers for lung cDC, namely
CD11c, MHCII, and CD11b [19] and Ab for intracyto-
plasmic portion of Sema4A for intracellular staining.
Using these markers, we found the presence of an intra-
cellular Sema4A in a specific subset of CD11c
intermed/
MHCII
low cells under allergic inflammatory conditions.
Lung tissue Tim-2 expression was also low (Figure 4 A
and 4C). These findings let us conclude that most prob-
ably lung tissue Sema4A-Tim-2 interaction, which is cri-
tical for T cell activation [32], might not be efficient
under the conditions studied. However, Sema4A protein
and its dimer were readily detected in the BAL fluids
obtained from OVA-challenged WT mice suggesting
that it can exert its activity as a locally released mole-
cule. In this study we used a protocol for an acute aller-
gic inflammatory response generation in mice. It is
possible that in chronic inflammatory conditions more
abundant cell surface Sema4A expression can be
detected. Additionally, Sema4A has been reported to be
present on endothelial cells [7], however, we could not
find it on lung endothelial cells using IHC with a corre-
sponding Ab defined in the Methods section. Although
lung Sema4A expression was upregulated by either aller-
gen or VEGF, it was still mainly targeted to APC-like
cells and underlining bronchial epithelium smooth mus-
cle cells (Figure 2 A). In contrast to its weak expression
in the lung tissue, a membrane-bound Sema4A was
readily detected in the lymphoid tissues by IHC (Figure
2 B) and specifically on spleen DC by flow cytometry
analysis (Figure 3 A and data not shown) where its
expression was upregulated in response to OVA treat-
ment on lung CD11c+MHCII- cell subset. Tim-2 was
also readily detected in lymphoid organs under allergic
inflammatory conditions (Figure 4 B). Therefore, the
lymphoid tissue membrane-bound Sema4A-Tim-2 inter-
action and the lung locally released Sema4A protein and
dimer could be critical for the allergic immune response
generation and regulation. Surprisingly, we found var-
ious cell types expressing low levels of Sema4A receptor
Tim-2 in the allergen-treated WT lungs and VEGF-
exposed lungs by IHC. The flow cytometry study has
shown that more than 25% of lung T cells expressed
Tim-2 in OVA-treated mice what corresponded to a 3-
fold increase over the baseline expression level found on
PBS-treated mouse lung T cells. As Tim-2 is a reported
marker mainly for Th2 cells [5,6], our data suggest
either that under the inflammatory conditions studied
Th2 cells represent a minor portion of lung infiltrating
T cells or that not all lung infiltrating Th2 cells are
Tim-2-positive.
In contrast to the relatively low lung tissue/cell
Sema4A and Tim-2 expression, the other neuroimmune
semaphorin and its immune cell receptor, namely
Sema4D and CD72, were found to be abundantly
expressed on many lung cells. A detection of Sema4D
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cell bundle pattern of molecule distribution (Figure 2 A)
whereas flow cytometry study with Ab to its extracellu-
lar portion was more definitive in targeting its expres-
sion to the specific cell subsets (Figure 3 A, C, and 3D;
Figure 5 B). Sema4D expression on lung cDC was very
low in PBS-treated lungs and was further downregulated
by allergen (Figure 3 A). It is currently well established
that lung cDC are critical APC for the allergic lung
immune response initiation and progression [33,34].
However, it is also well known that Sema4D exists in a
soluble form under inflammatory conditions. Therefore,
the identified subtle changes in cell-surface Sema4D
expression under allergic inflammation might not repre-
sent the local actual level of this molecule. Indeed, we
found the extracellular portion of Sema4D (120 kDa) in
the lung lysates under OVA-induced inflammation but
not in steady-state condition (Figure 2 C). High cell sur-
face Sema4D expression was detected on lung MHCII+
cells, T and B cells. MHCII+ cells (including DC) were
also found to express Sema4D immune cell receptor
CD72 (Figure 5 B). It has been shown previously for B
cells and DC that the addition of a soluble Sema4D pro-
tein or Sema4D-expressing cells to their cultures signifi-
cantly enhanced their CD40-induced proliferation and
differentiation [10,35]. Therefore, in addition to a direct
APC activation through T cell’s Sema4D and APC’s
CD72 [1,2,9-12] following a primary activation signal
(either the Ag stimulation or CD40-CD40L mediated
signal), there could be a potential autocrine Sema4D-
CD72-dependent mechanism of lung APC activation.
The release of a soluble Sema4D in the lung microenvir-
onment under inflammatory conditions where its recep-
tor CD72 is abundantly expressed on many lung
resident and inflammatory cells (Figure 5 A and 5B)
could provide an additional important local activation
signal for these cells.
Our data demonstrate the specific regulation of lung
immune semaphorins and their receptors in the aller-
gen-dependent (OVA-induced) and -independent
(VEGF-regulated) allergic airway inflammation. In con-
clusion, we show here that the expression of immune
semaphorins and their receptors in the lymphoid tissue
and lung tissue has some similarities as well as some
differences which need to be taken in account when
designing a strategy for the specific organ/tissue disease
intervention based on immune semaphorins as thera-
peutic molecular targets.
Conclusions
The understanding of the biology, distribution, and func-
tion of neuroimmune semaphorins Sema4A and Sema4D
is still in the early stage. Additional studies are needed to
define a detailed picture of each molecule and each
corresponding receptor regulation of the immune and
non-immune tissues and their roles in specific diseases.
Nevertheless, a current state of knowledge emerge neu-
roimmune semaphorins as critical regulatory molecules
with multiple distinct functions including immune cell
costimulation, regulation of cell morphology, adhesion,
and migration. Our study defines Sema4A, Sema4D, and
their receptors as potential markers and potential drug
targets for allergic airway inflammatory diseases.
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shows the photomicrographs of isotype control goat IgG stains of
mouse lung tissues.
Acknowledgements
The authors thank Jack A. Elias (Yale University) for VEGF tg mice.
This study was supported by NIH grants RO1AI59775 (ADK), RO1AI038985
(ADK) and R21AI076736 (SPC).
Author details
1Center for Vascular and Inflammatory Diseases, University of Maryland
School of Medicine, 800 West Baltimore St., Baltimore, Maryland 21201, USA.
2Department of Pathology, University of Maryland School of Medicine, 10
South Pine St., MSTF, Baltimore, Maryland 21201, USA.
3Department of
Microbiology and Immunology, University of Maryland School of Medicine,
685 West Baltimore St., HSF-I, Suite 380, Baltimore, Maryland 21201, USA.
4Program in Oncology, Marlene and Stewart Greenebaum Cancer Center,
University of Maryland School of Medicine, 22 South Greene St., Baltimore,
Maryland 21201, USA.
Authors’ contributions
EPS performed IHC, KS genotyped the tg mice and dissected control lungs,
MML and LJD analyzed lung tissue alterations and IHC, ADK provided
financial and mentorial support for the project, SPC designed the study,
performed flow cytometry experiments, captured IHC pictures, analyzed the
data, and drafted the manuscript. All authors read and approved the final
manuscript.
Received: 20 December 2010 Accepted: 19 May 2011
Published: 19 May 2011
References
1. Kumanogoh A, Kikutani H: Immune semaphorins: a new area of
semaphorin research. J Cell Sci 2003, 116:3463-3470.
2. Suzuki K, Kumanogoh A, Kikutani H: Semaphorins and their receptors in
immune cell interactions. Nat Immunol 2008, 9:17-23.
3. Gautier G, de Saint-Vis B, Senechal B, Pin JJ, Bates EE, Caux C, Geissmann F,
Garrone P: The class 6 semaphorin SEMA6A is induced by interferon-
gamma and defines an activation status of langerhans cells observed in
pathological situations. Am J Pathol 2006, 168:453-65.
4. Czopik AK, Bynoe MS, Palm N, Raine CS, Medzhitov R: Semaphorin 7A is a
negative regulator of T cell responses. Immunity 2006, 24:591-600.
5. Kumanogoh A, Shikina T, Suzuki K, Uematsu S, Yukawa K, Kashiwamura S,
Tsutsui H, Yamamoto M, Takamatsu H, Ko-Mitamura EP, Takegahara N,
Marukawa S, Ishida I, Morishita H, Prasad DV, Tamura M, Mizui M,
Toyofuku T, Akira S, Takeda K, Okabe M, Kikutani H: Nonredundant roles of
Sema4A in the immune system: defective T cell priming and Th1/Th2
regulation in Sema4A-deficient mice. Immunity 2005, 22:305-316.
Smith et al. BMC Immunology 2011, 12:30
http://www.biomedcentral.com/1471-2172/12/30
Page 13 of 146. Chakravarti S, Sabatos CA, Xiao S, Illes Z, Cha EK, Sobel RA, Zheng XX,
Strom TB, Kuchroo VK: Tim-2 regulates T helper type 2 responses and
autoimmunity. J Exp Med 2005, 202:437-444.
7. Toyofuku T, Yabuki M, Kamei J, Kamei M, Makino N, Kumanogoh A, Hori M:
Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses
angiogenesis via Plexin-D1. EMBO J 2007, 26:1373-1384.
8. Yukawa K, Tanaka T, Yoshida K, Takeuchi N, Ito T, Takamatsu H, Kikutani H,
Kumanogoh A: Sema4A induces cell morphological changes through B-
type plexin-mediated signaling. Int J Mol Med 2010, 25:225-230.
9. Delaire S, Elhabazi A, Bensussan A, Boumsell L: CD100 is a leukocyte
semaphorin. Cell Mol Life Sci 1998, 54:1265-1276.
10. Kumanogoh A, Suzuki K, Ch’ng E, Watanabe C, Takegahara N, Ishida I,
Sato T, Habu S, Yoshida K, Shi W, Kikutani H: Requirement for the
lymphocyte semaphorin, CD100, in the induction of antigen-specific T
cells and the maturation of dendritic cells. J Immunol 2002,
169:1175-1181.
11. Chabbert-de Ponnat I, Marie-Cardine A, Pasterkamp RJ, Schiavon V,
Tamagnone L, Thomasset N, Bensussan A, Boumsell L: Soluble CD100
functions on human monocytes and immature dendritic cells require
plexin C1 and plexin B1, respectively. Int Immunol 2005, 17:439-447.
12. Kumanogoh A, Kikutani H: Biological functions and signaling of
transmembrane semaphorin, CD100/Sema4D. Cell Mol Life Sci 2004,
61:292-300.
13. Fazzari P, Penachioni J, Gianola S, Rossi F, Eickholt BJ, Maina F,
Alexopoulou L, Sottile A, Comoglio PM, Flavell RA, Tamagnone L: Plexin-B1
plays a redundant role during mouse development and in tumour
angiogenesis. BMC Dev Bio 2007, 7:55.
14. Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A,
Winberg ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM:
Plexins are a large family of receptors for transmembrane, secreted, and
GPI-anchored semaphorins in vertebrates. Cell 1999, 99:71-80.
15. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, Kang MJ,
Cohn L, Kim YK, McDonald DM, Elias JA: Vascular endothelial growth
factor (VEGF) induces remodeling and enhances TH2-mediated
sensitization and inflammation in the lung. Nat Med 2004, 10:1095-1103.
16. Wang J, Homer RJ, Hong L, Cohn L, Lee CG, Jung S, Elias JA: IL-11
selectively inhibits aeroallergen induced pulmonary eosinophilia and
Th2 cytokine production. J Immunol 2000, 165:2222-2231.
17. Chapoval SP, Nabozny GH, Marietta EV, Raymond EL, Krco CJ, Andrews AG,
David CS: Short ragweed allergen induces eosinophilic lung disease in
HLA-DQ transgenic mice. J Clin Invest 1999, 103:1707-1717.
18. Kelly-Welch AE, Melo ME, Smith E, Ford AQ, Haudenschild C, Noben-
Trauth N, Keegan AD: Complex role of the IL-4 receptor alpha in a
murine model of airway inflammation: expression of the IL-4 receptor
alpha on nonlymphoid cells of bone marrow origin contributes to
severity of inflammation. J Immunol 2004, 172:4545-4555.
19. Chapoval SP, Lee CG, Tang C, Keegan AD, Cohn L, Bottomly K, Elias JA:
Lung vascular endothelial growth factor expression induces local
myeloid dendritic cell activation. Clin Immunol 2009, 132:371-384.
20. Chapoval SP, Al-Garawi A, Lora JM, Strickland I, Ma B, Lee PJ, Homer RJ,
Ghosh S, Coyle AJ, Elias JA: Inhibition of NF-kappaB activation reduces
the tissue effects of transgenic IL-13. J Immunol 2007, 179:7030-7041.
21. Wang H, Peters N, Laza-Stanca V, Nawroly N, Johnston SL, Schwarze J: Local
CD11c+ MHC class II- precursors generate lung dendritic cells during
respiratory viral infection, but are depleted in the process. J Immunol
2006, 177:2536-2542.
22. Landsman L, Jung S: Lung macrophages serve as obligatory intermediate
between blood monocytes and alveolar macrophages. J Immunol 2007,
179:3488-3494.
23. Wang X, Kumanogoh A, Watanabe C, Shi W, Yoshida K, Kikutani H:
Functional soluble CD100/Sema4D released from activated lymphocytes:
possible role in normal and pathologic immune responses. Blood 2001,
97:3498-3504.
24. Nakano H, Yanagita M, Gunn MD: CD11c(+)B220(+)Gr-1(+) cells in mouse
lymph nodes and spleen display characteristics of plasmacytoid
dendritic cells. J Exp Med 2001, 194:1171-1178.
25. Hochweller K, Miloud T, Striegler J, Naik S, Hämmerling GJ, Garbi N:
Homeostasis of dendritic cells in lymphoid organs is controlled by
regulation of their precursors via a feedback loop. Blood 2009,
114:4411-4421.
26. Debbabi H, Ghosh S, Kamath AB, Alt J, Demello DE, Dunsmore S, Behar SM:
Primary type II alveolar epithelial cells present microbial antigens to
antigen-specific CD4+ T cells. Am J Physiol Lung Cell Mol Physiol 2005, 289:
L274-L279.
27. Radsak M, Iking-Konert C, Stegmaier S, Andrassy K, Hansch GM:
Polymorphonuclear neutrophils as accessory cells for T-cell activation:
major histocompatibility complex class II restricted antigen-dependent
induction of T-cell proliferation. Immunology 2000, 101:521-530.
28. Hogaboam CM, Lukacs NW, Chensue SW, Strieter RM, Kunkel SL: Monocyte
chemoattractant protein-1 synthesis by murine lung fibroblasts
modulates CD4+ T cell activation. J Immunol 1998, 160:4606-4614.
29. Kambayashi T, Allenspach EJ, Chang JT, Zou T, Shoag JE, Reiner SL,
Caton AJ, Koretzky GA: Inducible MHC class II expression by mast cells
supports effector and regulatory T cell activation. J Immunol 2009,
182:4686-4695.
30. Roodink I, Verrijp K, Raats J, Leenders WP: Plexin D1 is ubiquitously
expressed on tumor vessels and tumor cells in solid malignancies. BMC
Cancer 2009, 9:297.
31. Basile JR, Castilho RM, Williams VP, Gutkind JS: Semaphorin 4D provides a
link between axon guidance processes and tumor-induced
angiogenesis. Proc Natl Acad Sci USA 2006, 103:9017-9022.
32. Kumanogoh A, Marukawa S, Suzuki K, Takegahara N, Watanabe C, Ch’ng E,
Ishida I, Fujimura H, Sakoda S, Yoshida K, Kikutani H: Class IV semaphorin
Sema4A enhances T-cell activation and interacts with Tim-2. Nature 2002,
419:629-633.
33. Lambrecht BN, Salomon B, Klatzmann D, Pauwels RA: Dendritic cells are
required for the development of chronic eosinophilic airway
inflammation in response to inhaled antigen in sensitized mice. J
Immunol 1998, 160:4090-4097.
34. van Rijt LS, Jung S, KleinJan A, Vos N, Willart M, Duez C, Hoogsteden HC,
Lambrecht BN: In vivo depletion of lung CD11c+ dendritic cells during
allergen challenge abrogates the characteristic features of asthma. J Exp
Med 2005, 201:981-991.
35. Kumanogoh A, Watanabe C, Lee I, Wang X, Shi W, Araki H, Hirata H,
Iwahori K, Uchida J, Yasui T, Matsumoto M, Yoshida K, Yakura H, Pan C,
Parnes JR, Kikutani H: Identification of CD72 as a lymphocyte receptor for
the class IV semaphorin CD100: a novel mechanism for regulating B cell
signaling. Immunity 2000, 13:621-31.
doi:10.1186/1471-2172-12-30
Cite this article as: Smith et al.: Expression of neuroimmune
semaphorins 4A and 4D and their receptors in the lung is enhanced by
allergen and vascular endothelial growth factor. BMC Immunology 2011
12:30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Smith et al. BMC Immunology 2011, 12:30
http://www.biomedcentral.com/1471-2172/12/30
Page 14 of 14